drugset / Trial / NCT03993106

A Study of sEphB4-HSA in Kaposi Sarcoma

NCT03993106

Phase 2 Unknown 65 enrolled Vasgene Therapeutics, Inc
NaSingle-groupOpen-labelTreatment

Summary

sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. The purpose of this study is to learn if sEphB4-HSA will decrease the number or size of Kaposi sarcoma lesions in people.

Timeline

Start
2020-09-17
Primary completion
2024-12
Completion
2025-06

Drugs

EvaluationDrugModalityDoseRoute
Subject sEphB4-HSA Protein / enzyme biologic Intravenous

Indications